Bcl-2 decreases voltage-gated K+ channel activity and enhances survival in vascular smooth muscle cells

D Ekhterae1, O Platoshyn, S Krick

  • 1Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of California School of Medicine, San Diego, California 92103, USA.

Insights

Overexpression of the anti-apoptotic protein Bcl-2 inhibits apoptosis in pulmonary artery smooth muscle cells. This effect is mediated by diminishing voltage-gated potassium (Kv) channel activity, suggesting a new mechanism for Bcl-2

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Cardiovascular Research

Background:

  • Cell shrinkage is a key indicator of apoptosis.
  • Potassium (K+) efflux partially causes apoptotic volume decrease.
  • Blocking K+ channels can reduce apoptosis.

Purpose of the Study:

  • To investigate if Bcl-2 inhibits apoptosis in pulmonary artery smooth muscle cells (PASMC).
  • To determine if Bcl-2 diminishes voltage-gated potassium (Kv) channel activity.
  • To explore the mechanism of Bcl-2's anti-apoptotic effect in vascular smooth muscle cells.

Main Methods:

  • Gene transfection using adenoviral vectors to overexpress Bcl-2 in PASMC.
  • Patch clamp electrophysiology to measure Kv currents (I(Kv)).
  • Single-cell PCR and fluorescence microscopy to analyze gene and protein expression.

Main Results:

  • Bcl-2 overexpression decreased Kv current amplitude and density.
  • The apoptosis inducer staurosporine (ST) increased I(Kv) in control cells but not in Bcl-2-overexpressing cells.
  • ST-induced apoptosis was significantly inhibited in Bcl-2-overexpressing cells.
  • Bcl-2 overexpression accelerated I(Kv) inactivation and downregulated Kv channel subunit mRNA.

Conclusions:

  • Bcl-2 inhibits apoptosis in PASMC by reducing Kv channel activity.
  • Inhibition of Kv channel activity is a potential mechanism for Bcl-2's anti-apoptotic function.
  • These findings offer insights into the role of Kv channels in vascular smooth muscle cell apoptosis.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Voltage-gated Ion Channels01:26

Voltage-gated Ion Channels

Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...